CTLA4 and melanoma: With respect to clinical trials for melanoma patients, as listed in clinicaltrials.gov (accessed on 7 October 2021), many studies combine BRAFi/MEKi with checkpoint inhibitors (CPI), such as pembrolizumab, nivolumab (both targeting PD-1), ipilimumab (targeting CTLA-4), or avelumab and atezolizumab (both targeting PD-L1) (NCT02818023, NCT03625141, NCT04722575, NCT02908672 NCT03554083, NCT02902029, NCT03149029, NCT02910700, NCT02858921, NCT01940809).